Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
Today, a brief rundown of news involving Astellas Pharma and Moderna, as well as updates from AstraZeneca, Daiichi Sankyo and Gilead Sciences that you may have missed. Astellas Pharma is planning new cost cuts as part of a strategic plan to achieve “ …